John "Lippy" Lippincott, PhD

Senior Vice President of Therapeutic Discovery Strategies at Alloy Discovery Services

Speaker

John Lippincott (“Lippy”) is Senior Vice President of Therapeutic Discovery Strategies at Alloy Discovery Services. He has over two decades of experience in the generation and characterization of antibodies from in vivo systems. Prior to joining the deeply experienced team at Alloy, Lippy established and led the hybridoma group at Pfizer’s San Diego site, where he was project leader for internal and co-development therapeutic discovery projects. At Igenica, he led the successful importation of a novel in vivo discovery platform and created a high-throughput system for hybridoma generation and screening, and led other processes required for identifying lead therapeutic candidates. Serving in the roles of Vice President, Antibody Discovery at LakePharma and then AlivaMab Discovery Services, Lippy built and led the teams responsible for providing superlative therapeutic antibody discovery services to clients. Lippy received his PhD from Harvard University and did postdoctoral research at the Genomics Institute of the Novartis Research Foundation in San Diego.